Survey of Third-Party Parenting Options Associated With Fertility Preservation Available to Patients With Cancer Around the Globe

Alexandra S Rashedi¹, Saskia F de Roo², Lauren M Ataman¹, Maxwell E Edmonds¹, Adelino Amaral Silva³, Anibal Scarella⁴, Anna Horbaczewska⁵, Antoinette Anazodo⁶, Ayse Arvas⁷, Bruno Ramalho de Carvalho⁸, Cassio Sartorio⁹, Catharina C M Beerendonk², Cesar Diaz-Garcia¹⁰, Chang Suk Suh¹¹, Cláudia Melo¹², Claus Yding Andersen¹³, Eduardo Motta¹⁴, Ellen M Greenblatt¹⁵, Ellen Van Moer¹⁶, Elnaz Zand¹⁷, Fernando M Reis¹⁸, Flor Sánchez¹⁹, Guillermo Terrado²⁰, Jhenifer K Rodrigues¹⁸, Joao Marcos de Meneses E Silva²¹, Johan Smitz¹⁶, Jose Medrano²², Jung Ryeol Lee¹¹, Katharina Winkler-Crepaz²³, Kristin Smith¹, Lígia Helena Ferreira Melo E Silva²¹, Ludwig Wildt²³, Mahmoud Salama²⁴, María Del Mar Andrés²², Maria T Bourlon²⁵, Mario Vega²⁶, Maurício Barbour Chehin²⁷, Michel De Vos²⁸, Mohamed Khrouf²⁹, Nao Suzuki³⁰, Osama Azmy²⁴, Paula Fontoura³¹, Paulo Henrique Almeida Campos-Junior³², Peter Mallmann³³, Ricardo Azambuja³⁴, Ricardo M Marinho³⁵, Richard A Anderson³⁶, Robert Jach⁵, Roberto de A Antunes³⁷, Rod Mitchell³⁶, Rouhollah Fathi¹⁷, Satish Kumar Adiga³⁸, Seido Takae³⁰, Seok Hyun Kim³⁹, Sergio Romero¹⁹, Silvana Chedid Grieco⁴⁰, Talya Shaulov⁴¹, Tatsuro Furui⁴², Teresa Almeida-Santos⁴³, Willianne Nelen², Yasmin Jayasinghe⁴⁴, Yodo Sugishita³⁰, Teresa K Woodruff¹

Affiliations

¹ Northwestern University, Chicago, IL.
² Radboud University Medical Center, Nijmegen, the Netherlands.
³ GENESIS-Center for Assistance in Human Reproduction, Rio de Janeiro, Brazil.
⁴ Universidad de Valparaiso, Valparaiso, Chile.
⁵ Jagiellonian University Medical College, Kraków, Poland.
⁶ University of New South Wales, Sydney, New South Wales.
⁷ Onkofertilite Turkiye, Istanbul, Turkey.
⁸ BONVENA-Reproductive Medicine, Brasília, Rio de Janeiro, Brazil.
⁹ Vida Centro de Fertilidade, Rio de Janeiro, Brazil.
¹⁰ University of Valencia, Valencia, Spain.
¹¹ Seoul National University College of Medicine, Seoul, South Korea.
¹² University of Coimbra, Coimbra, Portugal.
¹³ University of Copenhagen, Copenhagen, Denmark.
¹⁴ Federal University of São Paulo, São Paulo, Brazil.
¹⁵ University of Toronto, Toronto, Ontario, Canada.
¹⁶ Universitair Ziekenhuis Brussel, Jette, Belgium.
¹⁷ Royan Institute for Reproductive Biomedicine, Tehran, Iran.
¹⁸ Universidade Federal de Minas Gerais, Brazil.
¹⁹ Centro de Estudios e Investigaciones en Biología y Medicina Reproductiva, Lima, Peru.
²⁰ Pregna Medicina Reproductiva, Buenos Aires, Argentina.
²¹ Hemorrede do Ceará, Fortaleza, São João del-Rei, Brazil.
²² Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
²³ Medical University of Innsbruck, Innsbruck, Austria.
²⁴ National Research Center, Cairo, Egypt.
²⁵ Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
²⁶ IVF Centro de Reproduccion, Panama City, Panama.
²⁷ University of Santo Amaro, São Paulo, Brazil.
²⁸ Vrije Universiteit Brussel, Brussels, Belgium.
²⁹ Université de Tunis El Manar, Tunis, Tunisia.
³⁰ St Marianna University School of Medicine, Kawasaki, Japan.
³¹ Banco de Sêmen do Rio de Janeiro, Rio de Janeiro, Brazil.
³² Federal University of São João del-Rei, São João del-Rei, Brazil.
³³ University of Cologne, Cologne, Germany.
³⁴ Fertilitat Centro de Medicina Reprodutiva, Porto Alegre, Brazil.
³⁵ Pró-Criar Medicina Reprodutiva, Minas Gerais, Brazil.
³⁶ University of Edinburgh, Edinburgh, United Kingdom.
³⁷ Fertipraxis-Centro de Reprodução Humana, Rio de Janeiro, Brazil.
³⁸ Manipal University, Manipal, India.
³⁹ Seoul National University Hospital, Seoul, South Korea.
⁴⁰ IVI São Paulo-Chedid Grieco, São Paulo, Brazil.
⁴¹ University of Montreal Hospital Centre, Montreal, Quebec, Canada.
⁴² Gifu University School of Medicine, Gifu, Japan.
⁴³ Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
⁴⁴ Royal Women's Hospital, Melbourne, Victoria, Australia.

PMID: 32259159
PMCID: PMC7853875
DOI: 10.1200/JGO.2017.009944

Survey of Third-Party Parenting Options Associated With Fertility Preservation Available to Patients With Cancer Around the Globe

Alexandra S Rashedi et al. JCO Glob Oncol. 2020.

. 2020 Mar 2:6:JGO.2017.009944.

doi: 10.1200/JGO.2017.009944. eCollection 2020.

Authors

Affiliations

¹ Northwestern University, Chicago, IL.
² Radboud University Medical Center, Nijmegen, the Netherlands.
³ GENESIS-Center for Assistance in Human Reproduction, Rio de Janeiro, Brazil.
⁴ Universidad de Valparaiso, Valparaiso, Chile.
⁵ Jagiellonian University Medical College, Kraków, Poland.
⁶ University of New South Wales, Sydney, New South Wales.
⁷ Onkofertilite Turkiye, Istanbul, Turkey.
⁸ BONVENA-Reproductive Medicine, Brasília, Rio de Janeiro, Brazil.
⁹ Vida Centro de Fertilidade, Rio de Janeiro, Brazil.
¹⁰ University of Valencia, Valencia, Spain.
¹¹ Seoul National University College of Medicine, Seoul, South Korea.
¹² University of Coimbra, Coimbra, Portugal.
¹³ University of Copenhagen, Copenhagen, Denmark.
¹⁴ Federal University of São Paulo, São Paulo, Brazil.
¹⁵ University of Toronto, Toronto, Ontario, Canada.
¹⁶ Universitair Ziekenhuis Brussel, Jette, Belgium.
¹⁷ Royan Institute for Reproductive Biomedicine, Tehran, Iran.
¹⁸ Universidade Federal de Minas Gerais, Brazil.
¹⁹ Centro de Estudios e Investigaciones en Biología y Medicina Reproductiva, Lima, Peru.
²⁰ Pregna Medicina Reproductiva, Buenos Aires, Argentina.
²¹ Hemorrede do Ceará, Fortaleza, São João del-Rei, Brazil.
²² Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
²³ Medical University of Innsbruck, Innsbruck, Austria.
²⁴ National Research Center, Cairo, Egypt.
²⁵ Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
²⁶ IVF Centro de Reproduccion, Panama City, Panama.
²⁷ University of Santo Amaro, São Paulo, Brazil.
²⁸ Vrije Universiteit Brussel, Brussels, Belgium.
²⁹ Université de Tunis El Manar, Tunis, Tunisia.
³⁰ St Marianna University School of Medicine, Kawasaki, Japan.
³¹ Banco de Sêmen do Rio de Janeiro, Rio de Janeiro, Brazil.
³² Federal University of São João del-Rei, São João del-Rei, Brazil.
³³ University of Cologne, Cologne, Germany.
³⁴ Fertilitat Centro de Medicina Reprodutiva, Porto Alegre, Brazil.
³⁵ Pró-Criar Medicina Reprodutiva, Minas Gerais, Brazil.
³⁶ University of Edinburgh, Edinburgh, United Kingdom.
³⁷ Fertipraxis-Centro de Reprodução Humana, Rio de Janeiro, Brazil.
³⁸ Manipal University, Manipal, India.
³⁹ Seoul National University Hospital, Seoul, South Korea.
⁴⁰ IVI São Paulo-Chedid Grieco, São Paulo, Brazil.
⁴¹ University of Montreal Hospital Centre, Montreal, Quebec, Canada.
⁴² Gifu University School of Medicine, Gifu, Japan.
⁴³ Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
⁴⁴ Royal Women's Hospital, Melbourne, Victoria, Australia.

PMID: 32259159
PMCID: PMC7853875
DOI: 10.1200/JGO.2017.009944

Erratum in

Erratum.
[No authors listed] [No authors listed] JCO Glob Oncol. 2022 Mar;8:e2100412. doi: 10.1200/GO.21.00412. JCO Glob Oncol. 2022. PMID: 35275733 Free PMC article. No abstract available.

Abstract

Purpose: In the accompanying article, "Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe," we showed that specific fertility preservation services may not be offered at various sites around the world because of cultural and legal barriers. We assessed global and regional experiences as well as the legal status of third-party reproduction and adoption to serve as a comprehensive international data set and resource for groups that wish to begin oncofertility interventions.

Methods: We provide data on the legalities of third-party assisted reproductive technologies and other family-building options in the 28 oncofertility-practicing countries surveyed.

Results: We found regional and country differences that will be important in the development of tailored resources for physicians and for patient brochures that are sensitive to these local restrictions and cultural norms.

Conclusion: Because many patients first consult Web-based materials, the formal assessment of the availability of these options provides members of the global oncofertility community with data to which they might otherwise not have ready access to better serve their patients.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Alexandra S. RashediEmployment: Cigna (I) Stock or Other Ownership: Cigna (I)Antoinette AnazodoResearch Funding: Merck SeronoCassio SartorioEmployment: Vida Centro de Fertilidade Leadership: Vida Centro de Fertilidade Stock or Other Ownership: Vida Centro de FertilidadeCatharina C.M. BeerendonkTravel, Accommodations, Expenses: GoodlifeEllen M. GreenblattConsulting or Advisory Role: Ferring Pharmaceuticals, EMD Serono Travel, Accommodations, Expenses: EMD SeronoFernando M. ReisHonoraria: Politec Saúde (I) Consulting or Advisory Role: Politec Saúde (I) Speakers’ Bureau: UCB (I) Travel, Accommodations, Expenses: Abbott Laboratories (I)Flor SánchezPatents, Royalties, Other Intellectual Property: patent pendingJohan SmitzSpeakers’ Bureau: Ferring Pharmaceuticals Travel, Accommodations, Expenses: Ferring PharmaceuticalsMaria T. BourlonLeadership: Medivation, Astellas Pharma Honoraria: Medivation, Astellas PharmaRichard A. AndersonConsulting or Advisory Role: Roche, HRA Pharma, NeRe Pharmaceuticals Speakers’ Bureau: Roche, Beckman Coulter, IBSA Institut Biochimque Research Funding: Ferring Pharmaceuticals Travel, Accommodations, Expenses: IBSA Institut BiochimqueRoberto de A. AntunesConsulting or Advisory Role: Merck Serono Travel, Accommodations, Expenses: Merck Serono, MSDSergio RomeroPatents, Royalties, Other Intellectual Property: patent pendingTeresa Almeida-SantosConsulting or Advisory Role: Merck, MSD Research Funding: Merck SeronoTeresa K. WoodruffResearch Funding: Ferring Pharmaceuticals (Inst) No other potential conflicts of interest were reported.

References

1. Rashedi AS, de Roo SF, Ataman LM, et al: Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe. J Glob Oncol 10.1200/JGO.2016.008144. - DOI - PMC - PubMed
1. Wennberg AL, Rodriguez-Wallberg KA, Milsom I, et al. : Attitudes towards new assisted reproductive technologies in Sweden: A survey in women 30-39 years of age. Acta Obstet Gynecol Scand 95:38-44, 2016 - PubMed
1. Berg Brigham K, Cadier B, Chevreul K: The diversity of regulation and public financing of IVF in Europe and its impact on utilization. Hum Reprod 28:666-675, 2013 - PubMed
1. Loren AW, Mangu PB, Beck LN, et al. : Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500-2510, 2013 - PMC - PubMed
1. Lawson AK, Klock SC, Pavone ME, et al. : Psychological counseling of female fertility preservation patients. J Psychosoc Oncol 33:333-353, 2015 - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P50 HD076188/HD/NICHD NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Survey of Third-Party Parenting Options Associated With Fertility Preservation Available to Patients With Cancer Around the Globe

Affiliations

Survey of Third-Party Parenting Options Associated With Fertility Preservation Available to Patients With Cancer Around the Globe

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical